Luo Ying
Chief Executive Officer
Luo Ying has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: May 8, 2026.
On the most recent filing, Luo Ying is listed as Chief Executive Officer at GYRE THERAPEUTICS, INC. Inside the rolling window, Luo Ying reported no open-market purchases and 2 open-market sales totaling $83K in GYRE. The largest disclosed transaction in the window is a sale of 10,136 GYRE shares on May 6, 2026, worth $81K.
Companies traded
Other insiders at GYRE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$83K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Luo Ying made?
Luo Ying has filed 1 SEC Form 4 filing (2 transaction rows) across 1 company since 2026.
Which companies does Luo Ying trade?
Luo Ying has filed SEC Form 4 disclosures for 1 company, including GYRE.
When was Luo Ying's most recent SEC Form 4 filing?
Luo Ying's most recent SEC Form 4 filing on Tracefour is dated May 8, 2026.
What is Luo Ying's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Luo Ying is listed as Chief Executive Officer.
What is Luo Ying's total buy and sell value in the current window?
Inside the rolling retention window, Luo Ying bought $0 and sold $83K based on SEC Form 4 filings.
What was Luo Ying's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 10,136 GYRE shares on 2026-05-06, worth $81K, per SEC Form 4 filings.